Choriogonadotropin alfa - Merck Serono

Drug Profile

Choriogonadotropin alfa - Merck Serono

Alternative Names: Chorionic gonadotropin - Merck-Serono; Ovidrel; Ovitrelle; rhCG

Latest Information Update: 05 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Class Infertility therapies; Peptide hormones; Pituitary gonadotropins; Placental hormones; Recombinant proteins
  • Mechanism of Action Chorionic gonadotropin stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Female infertility
  • Discontinued Breast cancer; Hypogonadism; Male infertility

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top